Pages that link to "Q28290468"
Jump to navigation
Jump to search
The following pages link to Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis (Q28290468):
Displayed 26 items.
- Update on inflammatory bowel disease in patients with primary sclerosing cholangitis (Q24567496) (← links)
- A review of the medical treatment of primary sclerosing cholangitis in the 21st century (Q26771816) (← links)
- Molecular cancer prevention: Current status and future directions (Q26797207) (← links)
- Inflammatory bowel disease of primary sclerosing cholangitis: a distinct entity? (Q26994675) (← links)
- Inflammatory Bowel Disease and Primary Sclerosing Cholangitis: A Review of the Phenotype and Associated Specific Features (Q30234950) (← links)
- Colorectal Cancer and Dysplasia in Inflammatory Bowel Disease: A Review of Disease Epidemiology, Pathophysiology, and Management (Q30245054) (← links)
- In Barrett's esophagus patients and Barrett's cell lines, ursodeoxycholic acid increases antioxidant expression and prevents DNA damage by bile acids (Q33913295) (← links)
- Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: a review of the literature. (Q33958828) (← links)
- Metal Zn(II), Cu(II), Ni (II) complexes of ursodeoxycholic acid as putative anticancer agents (Q35644328) (← links)
- Primary sclerosing cholangitis: diagnosis, prognosis, and management (Q36955053) (← links)
- From Reflux Esophagitis to Esophageal Adenocarcinoma (Q37074161) (← links)
- Malignancies in Primary Sclerosing Cholangitis--A Continuing Threat (Q37082378) (← links)
- Ursodeoxycholic acid counteracts celecoxib in reduction of duodenal polyps in patients with familial adenomatous polyposis: a multicentre, randomized controlled trial (Q37113520) (← links)
- Association between Circulating Vitamin D Metabolites and Fecal Bile Acid Concentrations (Q37194017) (← links)
- Screening for malignancy in primary sclerosing cholangitis (PSC). (Q38383074) (← links)
- Chemoprevention of colorectal cancer in inflammatory bowel disease (Q39016806) (← links)
- Ursodeoxycholic acid inhibits the proliferation of colon cancer cells by regulating oxidative stress and cancer stem-like cell growth (Q41017557) (← links)
- Complications, symptoms, quality of life and pregnancy in cholestatic liver disease. (Q48331749) (← links)
- Patients With Ulcerative Colitis and Primary Sclerosing Cholangitis Frequently Have Subclinical Inflammation in the Proximal Colon. (Q53516705) (← links)
- Extraintestinal Manifestations of Inflammatory Bowel Disease. (Q55206226) (← links)
- Specific Features of Patients With Inflammatory Bowel Disease and Primary Sclerosing Cholangitis (Q61451061) (← links)
- An Overview on Primary Sclerosing Cholangitis (Q90307588) (← links)
- An update on treatment options for primary sclerosing cholangitis (Q92064845) (← links)
- British Society of Gastroenterology and UK-PSC guidelines for the diagnosis and management of primary sclerosing cholangitis (Q92465727) (← links)
- Malignancy in primary sclerosing cholangitis: Bile duct, liver, and colon (Q93140856) (← links)
- Bile acids modulate colonic MAdCAM-1 expression in a murine model of combined cholestasis and colitis (Q100416036) (← links)